All the news Showing 10 of 131 articles from: TreatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment for chronic hepatitis B linked to increased rates of colorectal and cervical cancer EASL press release / 15 April 2016 HIV/HBV co-infection linked to worse immune recovery and death, but tenofovir improves outcomes Liz Highleyman / 12 April 2016 HIV-positive people with hepatitis B virus (HBV) co-infection had impaired CD4 cell recovery after starting antiretroviral therapy (ART) and a higher risk of death than those without hepatitis B, but use of ... ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study ContraVir press release / 30 March 2016 Selected patients with chronic HBV may be able to discontinue antiviral treatment and maintain virological control Michael Carter / 29 March 2016 A substantial proportion of people receiving oral antiviral treatment for hepatitis B virus (HBV) may be able to achieve durable virological remission after the withdrawal of therapy, investigators report in Hepatology. Researchers conducted a ... J&J signs deal with Chinese company for hepatitis B drug Reuters / 08 January 2016 Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection Gilead press release / 05 January 2016 REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infection Liz Highleyman / 16 November 2015 The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load and increased anti-HBs antibody titres, according ... Johnson and Johnson acquires Novira to expand HBV pipeline Healio Hepatology / 11 November 2015 Using interferon with hepatitis B antivirals raises likelihood of HBsAg loss Liz Highleyman / 15 June 2015 Treating chronic hepatitis B with tenofovir plus pegylated interferon for 48 weeks resulted in a higher rate of hepatitis B surface antigen (HBsAg) clearance than either drug taken alone, though the response rate ... Hepatitis B patients on long-term entecavir or tenofovir have low mortality, but liver cancer remains a risk Liz Highleyman / 03 June 2015 More than 95% of people with chronic hepatitis B were still alive after five years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread) and most deaths were due to non-liver-related causes, according ... ← Prev1...678910...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds